BullFrog AI Announces Underwriter's Decision to Exercise Over-Allotment Option to Purchase 218,382 Shares of the Company's Common Stock
- GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced February 21, 2024, the Underwriter's decision to exercise their over-allotment option to purchase 218,382 shares of the Company's common stock (the “Option Shares”), pursuant to the Underwriting Agreement, dated January 31, 2024, by and between BullFrog AI Holdings, Inc. and WallachBeth Capital, LLC as representative of the Underwriters (the “Underwriting Agreement”).
- 02/21/2024
|
BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip
- GAITHERSBURG, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its CEO, Vin Singh, alongside distinguished guest, Daniel R. Weinberger, M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD), will participate in a fireside chat hosted by RedChip Companies on March 5, 2024 at 4:15 p.m. ET.
- 02/09/2024
|
WallachBeth Capital Announces Closing Of Bullfrog AI $5.7 Million Public Offering
- JERSEY CITY, N.J. , Feb. 5, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using (AI) and machine learning to enable the successful development of pharmaceuticals and biologics , has completed its previously announced underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and discount expenses.
- 02/05/2024
|
BullFrog AI Announces Closing of $5.7 Million Public Offering
- GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the closing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock (and/or Pre-Funded Warrants in lieu thereof) and/or warrants to purchase 226,071 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.
- 02/05/2024
|
WallachBeth Capital Announces Bullfrog AI Pricing of $5.7 Million Public Offering
- JERSEY CITY, N.J. , Feb. 1, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) a technology-enabled drug development company using (AI) and machine learning to enable the successful development of pharmaceuticals and biologics priced an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses.
- 02/01/2024
|
Bullfrog AI Announces Pricing of $5.7 Million Public Offering
- GAITHERSBURG, Md., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the pricing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock (and/or Pre-Funded Warrants in lieu thereof) and/or warrants to purchase 226,071 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.
- 02/01/2024
|
BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala
- GAITHERSBURG, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of two distinguished scientific advisors to its advisory board: Gwenn S. Smith, PhD, and Jeremiah Wala, MD, PhD.
- 01/26/2024
|
Bullfrog AI: advancing technologies in leaps and bounds
- If Bullfrog AI NASDAQ: BFRG is not on your radar yet, it should be. This company is an emerging leader in a subset of AI that will have one of the furthest-reaching impacts on humanity: drug discovery.
- 01/19/2024
|
Why Is Bullfrog AI (BFRG) Stock Up 30% Today?
- Shares of digital technology firm Bullfrog AI (NASDAQ: BFRG ) skyrocketed on Wednesday following an exciting development. Bullfrog, which specializes in leveraging machine learning to usher in a new era of precision medicine, was able to utilize its analytics technology to further the understanding and treatment of psychiatric disorders.
- 01/17/2024
|
This AI stock is up 30% on Wednesday: find out more
- Bullfrog AI Holdings Inc (NASDAQ: BFRG) says early results of its work with the Lieber Institute for Brain Development have been positive. Its shares are up 35% at writing.
- 01/17/2024
|
BullFrog AI's Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data
- GAITHERSBURG, Md., Jan. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced early results from its collaboration with the Lieber Institute for Brain Development (LIBD) that could revolutionize the understanding and treatment of psychiatric disorders. The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.
- 01/17/2024
|
BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
- GAITHERSBURG, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that the Australian Patent Office has issued Patent No.
- 01/16/2024
|
BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17
- GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, Chief Executive Officer of BullFrog AI, will present at the Webull LIVE! Healthcare Webinar on Wednesday, January 17, 2024.
- 01/11/2024
|
BullFrog AI Founder and CEO Vin Singh to Present Company Overview at BioFuture 2023
- GAITHERSBURG, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a presentation at BioFuture 2023 (Oct. 4-6, 2023) on the Company's recent partnerships, revenue and growth strategy, and portfolio of prodrugs in early-stage clinical development. The presentation will take place on October 5, 2023 at Lotte New York Palace in New York City.
- 09/25/2023
|
BullFrog AI Founder and CEO Vin Singh to Present Company Overview at Maxim Group's Emerging Growth in AI Virtual Tech Conference Series
- GAITHERSBURG, Md., Sept. 14, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a virtual presentation as part of Maxim Group's 2023 Virtual Tech Conference Series, Emerging Growth in AI, scheduled to take place from September 26-27, 2023, and hosted on M-VEST. The presentation will include an overview of the company and its programs with a Q&A for investors in virtual attendance to follow.
- 09/14/2023
|
7 AI Stocks With High Short Interest
- Under the view that the artificial intelligence mega-trend that emerged earlier this year has become an “AI bubble,” many on the short side have placed wagers against popular plays in the space. This has resulted in a growing number of AI stocks with high short interest.
- 08/07/2023
|
BullFrog AI: Soaring On Breaking News And AI Potential
- BullFrog AI NASDAQ: BFRG surged 44.22% higher yesterday on breaking news and traded almost 55 million shares. The digital pharmaceutical company encompassing artificial intelligence (AI) and machine learning (ML) could be a name to watch.
- 07/26/2023
|
BFRG Stock Alert: Why Is Bullfrog AI Up 30% Today?
- A major patent achievement has Bullfrog AI (NASDAQ: BFRG ) stock surging more than 30% today. This company is helping bring artificial intelligence (AI) to the development of pharmaceuticals and biologics.
- 07/25/2023
|
Generative AI to drive MedTech industry growth and innovation with failure to adopt key threat
- Generative artificial intelligence (AI) is poised to be a tailwind for the MedTech industry over the long term, analysts at UBS believe, with little pointing to AI being a threat in any way. In a note to clients following a conversation between the analysts and an expert in this area, they wrote that both generative AI and AI more broadly will bolster MedTech market growth by increasing procedural volumes as the technology leads to quicker and more accurate diagnosis.
- 06/12/2023
|
BullFrog AI CEO Vin Singh to Present at the Gujarati Physicians Convention 2023
- More than 1,000 physicians expected to attend the Continuing Medical Education program, where this year's scientific program theme is “Futuristic Medicine” More than 1,000 physicians expected to attend the Continuing Medical Education program, where this year's scientific program theme is “Futuristic Medicine”
- 06/09/2023
|
BullFrog AI CEO Vin Singh to Present at JMP Securities Life Sciences Conference
- GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced that Vin Singh, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:30 PM ET.
- 05/15/2023
|
3 Artificial Intelligence Stocks to Watch This Earnings Season
- Smart investors are keeping an eye on this hot new sector.
- 04/20/2023
|
Why Is BullFrog AI (BFRG) Stock Up 20% Today?
- On an otherwise slow Friday, machine learning specialist BullFrog AI (NASDAQ: BFRG ) got a head start to the weekend with an outstanding performance. Specifically, BFRG stock closed up by more than 20% today.
- 04/14/2023
|
Why Did Bullfrog AI Stock Jump More Than 50%?
- On April 4, 2023, Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) announced a new global licensing agreement with the Applied Physics Laboratory (APL) at Johns Hopkins University. Specifically, Bullfrog will provide APL access to its patented bfLEAP technology platform.
- 04/05/2023
|
BullFrog AI (BFRG) Stock Surges 30% on AI Licensing Agreement
- Shares of artificial intelligence (AI) specialist BullFrog AI (NASDAQ: BFRG ) — which focuses on streamlining data analytics in therapeutics development — popped dramatically higher against a down day for the equities sector. The catalyst for BFRG stock centered on the underlying enterprise inking a licensing agreement with a major laboratory.
- 04/04/2023
|
Best Penny Stocks For 2023? 3 To Watch In March
- Hot penny stocks to watch now. The post Best Penny Stocks For 2023?
- 03/06/2023
|
BullFrog AI to Present at Benzinga All Access Event on Friday, February 17
- GAITHERSBURG, MD / ACCESSWIRE / February 15, 2023 / BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a biopharmaceutical company focused on applying its proprietary Artificial Intelligence/Machine Learning platform to improve drug development and shorten clinical trial timelines, today announced that management will present during Benzinga's All Access investor event taking place Friday, February 17, 2023, at 11:00 a.m. ET. Vin Singh, Founder and CEO of BullFrog AI, is scheduled to host a presentation and Q&A session during the event as follows.
- 02/15/2023
|
